NASDAQ:TSBX Turnstone Biologics (TSBX) Stock Price, News & Analysis $0.59 -0.06 (-9.25%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.58▼$0.6450-Day Range$0.59▼$2.6552-Week Range$0.58▼$10.05Volume277,058 shsAverage Volume596,059 shsMarket Capitalization$13.61 millionP/E RatioN/ADividend YieldN/APrice Target$6.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Turnstone Biologics alerts: Email Address Turnstone Biologics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,068.2% Upside$6.88 Price TargetShort InterestHealthy1.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.90) to ($2.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.08 out of 5 starsMedical Sector301st out of 910 stocksBiological Products, Except Diagnostic Industry43rd out of 155 stocks 3.5 Analyst's Opinion Consensus RatingTurnstone Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTurnstone Biologics has only been the subject of 2 research reports in the past 90 days.Read more about Turnstone Biologics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.54% of the float of Turnstone Biologics has been sold short.Short Interest Ratio / Days to CoverTurnstone Biologics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Turnstone Biologics has recently increased by 47.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTurnstone Biologics does not currently pay a dividend.Dividend GrowthTurnstone Biologics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSBX. Previous Next 2.8 News and Social Media Coverage News SentimentTurnstone Biologics has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.Search Interest4 people have searched for TSBX on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Turnstone Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders32.10% of the stock of Turnstone Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.51% of the stock of Turnstone Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Turnstone Biologics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Turnstone Biologics are expected to grow in the coming year, from ($3.90) to ($2.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Turnstone Biologics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Turnstone Biologics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTurnstone Biologics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Turnstone Biologics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Turnstone Biologics Stock (NASDAQ:TSBX)Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.Read More TSBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSBX Stock News HeadlinesAugust 31, 2024 | americanbankingnews.comTurnstone Biologics Corp. (NASDAQ:TSBX) Short Interest UpdateAugust 19, 2024 | markets.businessinsider.comPiper Sandler Remains a Buy on Turnstone Biologics Corp. (TSBX)September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 16, 2024 | investing.comTurnstone reports positive early trial results for cancer therapyAugust 16, 2024 | markets.businessinsider.comTurnstone Biologics Corp. (TSBX) Gets a Hold from Leerink PartnersAugust 15, 2024 | benzinga.comTurnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy StudyAugust 15, 2024 | benzinga.comDow Surges Over 500 Points; US Retail Sales Rise In JulyAugust 15, 2024 | marketwatch.comTurnstone Biologics Shares Tumble Following Going Concern WarningSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 14, 2024 | investorplace.comTSBX Stock Earnings: Turnstone Biologics Misses EPS for Q2 2024August 14, 2024 | globenewswire.comTurnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business HighlightsAugust 14, 2024 | globenewswire.comTurnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal CancerAugust 13, 2024 | msn.comTurnstone Biologics Corp. (TSBX): This Penny Stock is a ‘Strong Buy’ According to AnalystsAugust 8, 2024 | 247wallst.com4 Stocks Under $5 To Buy NowMay 26, 2024 | uk.investing.comPiper Sandler reaffirms Overweight rating on Turnstone Biologics sharesMay 16, 2024 | markets.businessinsider.comLeerink Partners Reaffirms Their Hold Rating on Turnstone Biologics Corp. (TSBX)May 13, 2024 | investorplace.comTSBX Stock Earnings: Turnstone Biologics Misses EPS for Q1 2024May 13, 2024 | globenewswire.comTurnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business HighlightsSee More Headlines Receive TSBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSBX CUSIPN/A CIK1764974 Webturnstonebio.com Phone347-897-5988FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Target$6.88 High Stock Price Target$10.00 Low Stock Price Target$3.75 Potential Upside/Downside+1,068.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($10.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,200,000.00 Net MarginsN/A Pretax Margin-287.40% Return on Equity-85.18% Return on Assets-72.25% Debt Debt-to-Equity RatioN/A Current Ratio4.38 Quick Ratio4.38 Sales & Book Value Annual Sales$19.31 million Price / Sales0.70 Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book0.23Miscellaneous Outstanding Shares23,128,000Free Float15,704,000Market Cap$13.61 million OptionableNot Optionable Beta2.27 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Sammy J. Farah M.B.A. (Age 51)Ph.D., President, CEO & Director Comp: $820.88kDr. Venkat Ramanan Ph.D. (Age 54)Chief Financial Officer Comp: $613.14kDr. Vijay Chiruvolu M.B.A. (Age 62)Ph.D., Interim Chief Technology Officer Comp: $548.43kDr. Michael F. Burgess M.D. (Age 60)MBChB, Ph.D., Interim Chief Medical Officer & Executive Director Dr. Stewart Abbot Ph.D. (Age 57)Chief Scientific Officer Ms. Saryah Azmat (Age 34)Chief Business Officer Comp: $479.73kMore ExecutivesKey CompetitorsAileron TherapeuticsNASDAQ:ALRNKronos BioNASDAQ:KRONIO BiotechNASDAQ:IOBTCalidi BiotherapeuticsNYSE:CLDIVolitionRxNYSE:VNRXView All CompetitorsInstitutional OwnershipPoint72 Asset Management L.P.Sold 65,300 shares on 8/19/2024Ownership: 4.837%Sei Investments Co.Bought 11,882 shares on 8/13/2024Ownership: 0.051%View All Institutional Transactions TSBX Stock Analysis - Frequently Asked Questions How have TSBX shares performed this year? Turnstone Biologics' stock was trading at $2.55 on January 1st, 2024. Since then, TSBX stock has decreased by 76.9% and is now trading at $0.5885. View the best growth stocks for 2024 here. How were Turnstone Biologics' earnings last quarter? Turnstone Biologics Corp. (NASDAQ:TSBX) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.08. When did Turnstone Biologics IPO? Turnstone Biologics (TSBX) raised $80 million in an IPO on Friday, July 21st 2023. The company issued 6,666,667 shares at $12.00 per share. Who are Turnstone Biologics' major shareholders? Turnstone Biologics' top institutional shareholders include Point72 Asset Management L.P. (4.84%) and Sei Investments Co. (0.05%). Insiders that own company stock include Rishi Gupta and Versant Ventures V, Llc. View institutional ownership trends. How do I buy shares of Turnstone Biologics? Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSBX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TSBX Stock Alerts